Taken directly from JACC
Over the last 4 decades, percutaneous coronary intervention has evolved dramatically and is now an acceptable treatment option for patients with advanced coronary artery disease. However, trialists have struggled to establish the respective roles for percutaneous coronary intervention and coronary artery bypass graft surgery, especially in patients with multivessel disease and unprotected left-main stem coronary artery disease.
Several pivotal trials and meta-analyses comparing these two revascularisation strategies have enabled the relative merits of each technique to be established with regard to the type of ischaemic syndrome, the coronary anatomy, and the patient’s overall comorbidity. Precision medicine with individualised prognosis is emerging as an important method of selecting treatment.
However, the never-ending advancement of technology, in conjunction with the emergence of novel pharmacological agents, will in the future continue to force us to reconsider the evolving question: “Which treatment strategy is better and for which patient?”
Read in full here: https://www.jacc.org/doi/10.1016/j.jacc.2021.05.024
Reference:
Serruys PW, Ono M, Garg S, Hara H, Kawashima H, Pompilio G, Andreini D, Holmes DR Jr, Onuma Y, King Iii SB. Percutaneous Coronary Revascularization: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol. 2021 Jul 27;78(4):384-407. doi: 10.1016/j.jacc.2021.05.024. PMID: 34294273.
